Clinical predictors for long-term benefit of cetuximab maintenance therapy – Single center subanalysis of the GEMTAX IV trial

S. Rüdiger, C. Kropf, G. Schmid-Bindert, T. Wibmer, M. Lanzinger, K. Stoiber, J. Blanta, W. Rottbauer, C. Schumann (Ulm, Mannheim, Germany)

Source: Annual Congress 2011 - Palliation and morbidity in lung cancer patients
Session: Palliation and morbidity in lung cancer patients
Session type: Thematic Poster Session
Number: 2778
Disease area: Thoracic oncology

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Rüdiger, C. Kropf, G. Schmid-Bindert, T. Wibmer, M. Lanzinger, K. Stoiber, J. Blanta, W. Rottbauer, C. Schumann (Ulm, Mannheim, Germany). Clinical predictors for long-term benefit of cetuximab maintenance therapy – Single center subanalysis of the GEMTAX IV trial. Eur Respir J 2011; 38: Suppl. 55, 2778

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
STIT-1: Evaluation of safety and efficacy of short-time TNI treatment in patients with COPD – First interim analysis
Source: Annual Congress 2010 - Exercise in respiratory diseases and oxygen therapy
Year: 2010

Cognitive function of patients with COPD after virtual admission – A randomized clinical trial
Source: Annual Congress 2012 - COPD comorbidities II
Year: 2012


Differences in therapy for stable COPD across Europe – Results of a multicenter study
Source: Annual Congress 2010 - Airway responsiveness, chronic cough and bronchiectasis: a modern approach
Year: 2010

The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Consistent benefit across multiple exacerbation endpoints
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019


Tolerability and efficacy of budesonide/formoterol via Turbuhaler® vs standard treatment in Japanese patients with moderate to severe COPD: 52-week phase III study results
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012


Efficacy and safety of once-daily single-inhaler triple therapy in patients with inadequately controlled asthma: the CAPTAIN trial
Source: Breathe, 17 (1) 200279; 10.1183/20734735.0279-2020
Year: 2021



Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial
Source: Virtual Congress 2020 – Pharmacological management of COPD
Year: 2020


Assessment of costs and outcomes of chemotherapy in an observational setting in patients with advanced NSCLC (ACTION)
Source: Eur Respir J 2004; 24: Suppl. 48, 304s
Year: 2004

Cost-effectiveness of single- vs multiple-inhaler triple therapy in a UK COPD population: INTREPID trial
Source: Virtual Congress 2021 – Highlights for primary care in 2021
Year: 2021



Safety and benefit of adjunctive systemic corticosteroid therapy in the management of severe, smear positive pulmonary tuberculosis (SSP-PTB); an interim analysis of a randomized controlled trial
Source: Annual Congress 2012 - Tuberculosis: clinical findings II
Year: 2012


Patient education via tablet-pc vs. conventional to improve compliance with immunosuppressive drug regimen after lung transplantation - a randomized controlled trial
Source: Annual Congress 2013 –Clinical studies in lung transplantation
Year: 2013


Long term results of the randomized phase 2 trial on refinement of early stage NSCLC adjuvant chemotherapy with cisplatin/pemetrexed (CPx) versus cisplatin/vinorelbine (CVb) - TREAT
Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours
Year: 2014

Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial
Source: Annual Congress 2009 - Functional insights into COPD
Year: 2009

Late Breaking Abstract - Long-term safety and efficacy of benralizumab in severe, uncontrolled asthma: first results of BORA, a randomized, Phase III extension study
Source: International Congress 2018 – Notable Studies in Asthma
Year: 2018



Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial
Source: Eur Respir J, 56 (6) 2002808; 10.1183/13993003.02808-2020
Year: 2020



Cardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT?
Source: ERJ Open Res 2016: 00055-2016
Year: 2016



Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial.
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018


A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol
Source: Eur Respir J 2016; 48: 320-330
Year: 2016



CompERA-XL: International, prospective registry for the documentation of first-line and maintenance therapy in patients with pulmonary hypertension
Source: Annual Congress 2010 - Pulmonary hypertension
Year: 2010


Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013